SH
VRTX icon

SLT Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

SLT Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$250K Buy
503
+20
+4% +$8.86K 0.16% 126
2026
Q1 		$216K Buy
+483
New +$225K 0.15% 121

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
FAF
Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

SLT Holdings's VRTX Position: Q2 2026 in Review

SLT Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 4.1% in Q2 2026, buying an estimated $8.86K and bringing the position to 503 shares worth $250K. The position accounts for 0.16% of the portfolio, ranked #126.

SLT Holdings first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 605 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • SLT Holdings held 503 shares of Vertex Pharmaceuticals worth $250K as of Q2 2026.
  • SLT Holdings bought 20 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.86K.
  • Vertex Pharmaceuticals made up 0.16% of SLT Holdings's portfolio in Q2 2026, its #126 holding.
  • SLT Holdings first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 605 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on SLT Holdings's 13F filing for Q2 2026, filed 17 Jul 2026.